Aliskiren--mode of action and preclinical data

Area of Science:

• Cardiovascular pharmacology
• Renal physiology
• Drug discovery

Background:

• Hypertension is a global health issue, increasing risks for cardiovascular and renal diseases.
• The renin-angiotensin system (RAS) is crucial for blood pressure regulation.
• Direct renin inhibition was a therapeutic challenge until the development of aliskiren.

Purpose of the Study:

• To introduce aliskiren, a novel direct renin inhibitor, as a new therapeutic option for hypertension.
• To present preclinical data on aliskiren's effects in a transgenic rat model.
• To summarize initial human study findings on aliskiren's efficacy and safety.

Main Methods:

• Utilized a novel transgenic rat model with human renin and angiotensinogen genes.
• Administered aliskiren, a small-molecule direct renin inhibitor.
• Reviewed preclinical and early human clinical data.

Main Results:

• Aliskiren demonstrated a prolonged half-life and favorable pharmacokinetics.
• Preclinical studies showed reduced mortality, cardiac hypertrophy, arrhythmias, proteinuria, and inflammation.
• Human studies indicated effective blood pressure reduction with a good side effect profile.

Conclusions:

• Aliskiren represents a new class of antihypertensive drugs targeting the rate-limiting step of RAS.
• Preclinical findings suggest potential benefits in mitigating target-organ damage.
• Further clinical trials are necessary to confirm aliskiren's long-term clinical utility in managing hypertension.